CytomX Therapeutics Receives $20,000,000 Series C Financing

  • Feed Type
  • Date
  • Company Name
    CytomX Therapeutics
  • Mailing Address
    343 Oyster Point Blvd. South San Francisco, CA 94080 USA
  • Company Description
    CytomX Therapeutics is an early stage, privately-funded biotechnology company developing Probodies, proteolytically-activated antibodies.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series C
  • Proceeds Purposes
    The proceeds from this financing will help enable CytomX to advance our proprietary pipeline of Probody Drug Conjugates and Probodies against cancer immunotherapy checkpoint targets towards the clinic, while we also pursue Probody applications with bispecific antibodies and engineered T-cell therapies.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy